Clinical trials: Trametinib
Melanoma
Trametinib With GSK2141795 in BRAF Wild-type Melanoma
This is a multicenter phase II clinical study of trametinib in combination with GSK2141795 in patients with BRAF wild-type mutation melanoma.
- Trial name
- NCT01941927
- Testing
- Trametinib (GSK1120212), GSK2141795
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Adil Daud
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
This phase II trial studies how well dabrafenib, trametinib, and spartalizumab works in treating patients with BRAF V600E or V600K mutation positive stage IIIB/C/D melanoma, who do not achieve a pathologic complete response after…
- Conditions
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Trial name
- NCT04310397
- Testing
- Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Brain
Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
This phase I trial studies the side effects and best dose of trametinib with or without whole brain radiation therapy in treating patients with brain metastases.
- Trial name
- NCT02015117
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well trametinib works in treating patients with hormone-resistant prostate cancer that is growing or getting worse and has spread to other parts of the body.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02881242
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Trametinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma
An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
The goal of this clinical research study is to learn if the combination of 2 drugs dabrafenib and trametinib can help to control melanoma that has or has not spread to the brain.
- Trial name
- NCT01619774
- Testing
- GSK2118436, GSK1120212
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Prostate cancer is the most common cancer in men and the second leading cause of cancer death in men. The purpose of this research study is to compare prostate cancers treated with hormone therapy versus prostate cancers treated…
- Trial name
- NCT01990196
- Testing
- degarelix, enzalutamide, trametinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Soft Tissue Sarcoma
Molecular Profiling of Advanced Soft-tissue Sarcomas
MULTISARC is a randomized multicenter study assessing whether high throughput molecular analysis (next generation sequencing exome - NGS) is feasible in advanced/metastatic soft-tissue sarcoma patients, that is, whether NGS can…
- Trial name
- MULTISARC (NCT03784014)
- Testing
- Nilotinib, Ceritinib, Capmatinib
- Where
- 17 sites in France
- Volunteers
- 603 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Refractory Differentiated Thyroid Gland Carcinoma
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which…
- Trial name
- NCT06475989
- Testing
- Biospecimen Collection, Cabozantinib, Computed Tomography
- Where
- 307 sites in United States
- Volunteers
- 264 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cancer, Tumors
The Drug Rediscovery Protocol (DRUP Trial)
This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs* prescribed for treatment of patients with advanced cancer with a…
- Conditions
- Cancer, Tumors, Neoplasm, Neoplasia
- Trial name
- DRUP (NCT02925234)
- Testing
- Panitumumab, Olaparib, Dabrafenib
- Where
- 36 sites in Netherlands
- Volunteers
- 1,550 people
- Sponsor
- The Netherlands Cancer Institute
Malignant Melanoma
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
The primary objective for this non-interventional study was to assess the quality of life of melanoma patients under adjuvant treatment with dabrafenib and trametinib in real world setting in Portugal through disease specific…
- Trial name
- NCT04547946
- Testing
- dabrafenib + trametinib
- Where
- 2 sites in Portugal
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Cancer, Thyroid Neoplasms
Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as…
- Trial name
- NeoLATC (NCT07419932)
- Testing
- Multitarget Tyrosine Kinase Inhibitors, BRAF inhibitor dabrafenib and MEK inhibitor trametinib, RET Inhibitor
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
Neoplasms
A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and toxicity of irinotecan with dabrafenib, cetuximab/panitumumab in the second line of treatment for the potential treatment of colorectal cancer that: has a metastatic…
- Trial name
- NCT06967155
- Testing
- • Drug: Dabrafenib • Drug: Trametinib • Drug: Cetuximab • Drug: Рanitumumab • Drug: Oxaliplatin • Drug: Irinotecan • Drug: Leucovorin • Drug: 5-FU
- Where
- Russia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
This is a single arm phase II trial focused on how dabrafenib and trametinib before and after surgery works in treating patients with stage IIIB-C melanoma that has a specific mutation in the BRAF gene.
- Trial name
- NCT02231775
- Testing
- Dabrafenib, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Neurofibromatosis 1, Child
Treatment of NF1-related Plexiform Neurofibroma With Trametinib
This trial, Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm,open-label study with the goals of volumetric partial remission and pain relief (EudraCT 2018-001846-32, Sponsor protocol number BUS2018-1…
- Conditions
- Neurofibromatosis 1, Child, Neurofibroma, Plexiform
- Trial name
- plexifpc (NCT03741101)
- Testing
- Trametinib
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Region Skane
Follicular Thyroid Cancer, Insular Thyroid Cancer
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer.
- Conditions
- Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
- Trial name
- NCT01723202
- Testing
- dabrafenib, trametinib
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bhavana Konda
Metastatic Melanoma
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: Pembrolizumab (Keytruda) Trametinib (Mekinist) Dabrafenib (Tafinlar)
- Trial name
- NCT03149029
- Testing
- Pembrolizumab, Dabrafenib, Trametinib
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Melanoma
CAcTUS - Circulating Tumour DNA Guided Switch
The stay aims to determine whether switching from targeted therapy to immunotherapy based on a decrease in levels of circulating tumour DNA in the blood, will improve the outcome in melanoma patients.
- Trial name
- CAcTUS (NCT03808441)
- Testing
- ctDNA analysis
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- The Christie NHS Foundation Trust
RAS Mutation, Ras (Kras or Nras) Gene Mutation
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the…
- Conditions
- RAS Mutation, Ras (Kras or Nras) Gene Mutation, Colorectal Cancer Recurrent, Pancreas Cancer
- Trial name
- NТО-RAS (NCT06229340)
- Testing
- Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab
- Where
- Russia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumours
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
This is an open-label, multi-center, dose-finding Phase 1 study that will enroll subjects at least 18 years old with unresectable or metastatic melanoma and BRAF V600 mutations.
- Trial name
- NCT01767454
- Testing
- Dabrafenib, Trametinib, Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline